EUVIMEDEUVIMED entdecken
Crossref

What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses

Lubomír Minařík

Transfuze a hematologie dnes · 10.03.2026 · 32 (1)

DOI: 10.48095/cctahd202605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfuze a hematologie dnes, online erschienen am 06.03.2026. Verfasst von Lubomír Minařík.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Minařík, L. (2026). What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses. Transfuze a hematologie dnes, 32(1). https://doi.org/10.48095/cctahd202605

Vancouver

Minařík L. What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses. Transfuze a hematologie dnes. 2026;32(1). doi:10.48095/cctahd202605

BibTeX
@article{Minak2026,
  author = {Minařík, Lubomír},
  title = {What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses},
  journal = {Transfuze a hematologie dnes},
  year = {2026},
  volume = {32},
  number = {1},
  doi = {10.48095/cctahd202605}
}
Kostenlos starten →